Kanglin Biotechnology Announces $20 Million Series A Financing to Advance the Development of Gene Therapies
November 25, 2024 07:00 ET
|
Kanglin Biotec
- Phase 1 study and Investigator Initiated Trial evaluating KL003 for patients with beta thalassemia demonstrated an encouraging efficacy signal and favorable safety profile – - Manufacturing costs...
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
November 07, 2024 08:07 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Asklepios...
AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024
October 17, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical...
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
September 25, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AskBio and Belief BioMed will work together to advance potential gene...
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
July 11, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of...
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
June 25, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic...
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
May 02, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG,...
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
April 18, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is being studied for the treatment of adults with non-ischemic...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
AskBio Names Mansuo Shannon Chief Scientific Officer
April 09, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyCo-Founder and former Chief...